Physician profile
John Abraham
NPI 1952045478
$3,811.87
in general payments reported to CMS, 2019-2025
12 companies · $770 in 2025
The $770 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $1,183 · 2024: $1,738 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,690.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,050.10 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $622.96 | 2023-2025 | |
| Abbvie INC. | $469.17 | 2023-2025 | Vraylar, Botox |
| Novo Nordisk INC | $374.32 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.31 | 2024-2025 | Jardiance |
| Acadia Pharmaceuticals INC | $242.72 | 2023 | Nuplazid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.98 | 2025 | Xifaxan |
| Amgen INC. | $122.14 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $122.14 | 2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $121.85 | 2022 | |
| Bioxcel Therapeutics, INC. | $109.80 | 2023 | Igalmi |
| Arcutis Biotherapeutics, INC. | $109.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.